trending Market Intelligence /marketintelligence/en/news-insights/trending/TfuSD8XJsP7LDvqvPWN4JQ2 content esgSubNav
In This List

Lexicon's oral diabetes drug meets primary endpoint in phase 3 study

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Lexicon's oral diabetes drug meets primary endpoint in phase 3 study

Lexicon Pharmaceuticals Inc.'s investigational, oral diabetes drug sotagliflozin met its primary endpoint in a phase 3 clinical trial.

The company was studying the treatment in type 1 diabetes patients who were on insulin therapy. The study met its primary endpoint after demonstrating superiority over placebo and a well-tolerated safety profile during a 24-week treatment period.

Results from the study will be submitted for publication in a peer-reviewed journal.

The drug is also being studied in adults with type 2 diabetes.